BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 33278557)

  • 1. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-positive (ER
    Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
    Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
    Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
    Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
    J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER
    Amaral C; Trouille FM; Almeida CF; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2021 Jun; 210():105876. PubMed ID: 33722705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated Exposure to 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP), an Active Metabolite of Bisphenol A, Aggressively Stimulates Breast Cancer Cell Growth in an Estrogen Receptor
    Hirao-Suzuki M; Takeda S; Okuda K; Takiguchi M; Yoshihara S
    Mol Pharmacol; 2019 Mar; 95(3):260-268. PubMed ID: 30552153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
    Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
    Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
    Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
    Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
    Nehybova T; Smarda J; Daniel L; Brezovsky J; Benes P
    J Steroid Biochem Mol Biol; 2015 Aug; 152():76-83. PubMed ID: 25934092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP) Targets Estrogen Receptor β, to Evoke the Resistance of Human Breast Cancer MCF-7 Cells to G-1, an Agonist for G Protein-Coupled Estrogen Receptor 1.
    Hirao-Suzuki M; Nagase K; Suemori T; Tsutsumi K; Shigemori E; Tanaka M; Takiguchi M; Sugihara N; Yoshihara S; Takeda S
    Biol Pharm Bull; 2021; 44(10):1524-1529. PubMed ID: 34602561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptors in breast carcinogenesis and endocrine therapy.
    Huang B; Warner M; Gustafsson JÅ
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():240-4. PubMed ID: 25433206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
    Zhao LM; Jin HS; Liu J; Skaar TC; Ipe J; Lv W; Flockhart DA; Cushman M
    Bioorg Med Chem; 2016 Nov; 24(21):5400-5409. PubMed ID: 27647367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
    Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
    J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.